Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty

Journal of the American College of Cardiology

Volumn 27, Issue 3, 1996, Pages 536-542

  Kereiakes, Dean J ^a   Kleiman, Neal S ^b   Ambrose, John ^c   Cohen, Marc ^d   Rodriguez, Samuel ^e   Palabrica, Theresa ^f   Herrmann, Howard C ^g   Sutton, Joseph M ^h   Weaver, W Douglas ⁱ   McKee, Donna B ^j   Fitzpatrick, Virginia ^j   Sax, Frederic L ^j  

^a CHRIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

^d HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^e UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; PLACEBO; THROMBOCYTE RECEPTOR; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 9044234402     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(95)00500-5     Document Type: Article

References (30)

1. de Feyter PJ, van den Brend M, Jaarman G, et al. Acute coronary occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management and follow up. Circulation 1991;83: 927-36.
2. Detre KM, Holmes DR, Holubkov R, et al. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Coronary Angioplasty Registry. Circulation 1990;82: 739-50.
3. Lincoff AM, Popma J, Ellis S, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-35.
4. Minar E, Ehringer H, Ahmadi R, Dudczek R, Porenta G. Platelet deposition at angioplasty site and platelet survival time after PTA in iliac and femoral arteries: Investigations with indium-111-oxide labeled platelets in patients with ASA (1.0 g/D) therapy. Thromb Haemost 1987;58:718-23.
5. Badimon L, Badimon JJ, Gallvez A, Chesebro JH, Fuster V. Influence of arterial wall damage and wall sheer rate on platelet deposition: ex vivo study in a swine model. Arteriosclerosis 1986;6:312-20.
6. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP. Platelet accumulation in experimental angioplasty: time course in relation to cardiovascular injury. Circulation 1987;75:636-42.
7. Mabin TA, Holmes DR, Smith HC, et al. Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;3:198-202.
8. Smyth SS, Joneckis CC, Parise LV. Regulation of vascular integrins. Blood 1993;81:2827-43.
9. Leung L, Nachman R. Molecular mechanisms of platelet aggregation. Annu Rev Med 1986;37:179-86.
10. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988;71:831-43.
11. Coller BS. Platelets in thrombolytic therapy. N Engl J Med 1990;322:33-42.
12. Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent postangioplasty restenosis and thrombosis. J Am Coll Cardiol 1991;17:89B-95B.
13. Azrin MA, Todd MB, Chen Q, Tselentakis M, Ezekowitz MD. The effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa on restenosis after angioplasty in a rabbit model. Circulation 1991;84 Suppl II:II-332.
14. Bates ER, McGillem MJ, Mickelson JK, Pitt B, Mancini GB. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 1991;84:2463-9.
15. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-61.
16. Lynch JJ, Cook JJ, Sitko GR, et al. Non-peptide glycoprotein IIb/IIIa inhibitors. Five antithrombotic effects of MK-383. J Pharmacol Exp Ther 1995;272:20-32.
17. Peerlinck K, DeLepeleire I, Goldberg M, et al. MK-383-a selective, non-peptide platelet glycoprotein IIb/IIIa antagonist is active in man. Circulation 1993;88:1512-7.
18. Barrett JS, Murphy MG, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein IIb/IIIa receptor antagonist in healthy men. Clin Pharmacol Ther 1994;56:377-88.
19. ACC/AHA Task Force Report. Guidelines for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1988;12:529-45.
20. Ellis SG, Vandormael MG, Cowley MJ, et al. Multivessel Angioplasty Prognosis Study Group. Coronary morphological and clinical determinants of procedural outcome with angioplasty to multivessel coronary disease. Circulation 1990;82:1193-202.
21. Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous "veno-stasis" bleeding time technique. J Lab Clin Med 1941;26: 1812-22.
22. Yasuda T, Gold HK, Fallon JT. et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue type plasminogen activator. J Clin Invest 1988;81:1284-91.
23. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in adult models. Circulation 1988;77:670-7.
24. Ellis SG, Tcheng JE, Navetta FI, et al. Safety in antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis 1993;4:167-75.
25. Sutton JM, Anderson K. EPIC Study Group: Body weight and heparin dosing influence bleeding complications with c7E3 antiplatelet antibody [abstract]. Circulation 1993;88 Suppl I:I-209.
26. Lincoff AM, Tcheng JE, Bass TA, et al. A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with the platelet GP IIb/IIIa receptor antibody c7E3 during percutaneous coronary revascularization [abstract]. J Am Coll Cardiol 1995;25:80A.
27. Tcheng JE. Dosing and administration of ReoPro (c7E3 fab). J Invas Cardiol 1994;6 Suppl A:29A-33A.
28. Holmes DR, Holubkov R, Vlietstra RE, et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977-1981 and from 1985-1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1988; 12:1149-55.
29. Popma JE, Satler LF. Early and late clinical outcomes following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC trial results. J Invas Cardiol 1994;6 Suppl A:19A-28A.
30. Lincoff AM, Califf RM, Anderson K, Weisman HF, Topol EJ. Striking clinical benefit with platelet GP IIb/IIIa inhibition by c7E3 among patients with unstable angina: outcome in the EPIC trial [abstract]. Circulation 1994;90 Suppl I:I-21.